Adults and Children over 110 lb: PO 250 mg twice daily initially (for 1 wk), followed by 500 mg twice daily. For maintenance therapy, may reduce by 500 mg every 6 mo until serum uric acid increases.
In Conjunction with Antibiotic Therapy PO 2 g/day in divided doses.
Children 2 to 14 yr (under 110 lb): PO 25 mg/kg or 0.7 g/m2 initially. Maintenance dose is 40 mg/kg/day or 1.2 g/m2 , divided into 4 doses.
Inhibits tubular reabsorption of urate, thus increasing urinary excretion of uric acid. Inhibits tubular secretion of most penicillin and cephalosporin antibiotics.
Children less than 2 yr; blood dyscrasias or uric acid kidney stones. Do not start therapy until acute gout attack subsides.
Use Cautiously in:
CNS: Headaches; dizziness.
DERM: Dermatitis; pruritus.
GI: Anorexia; nausea; GI distress; vomiting; sore gums.
GU: Urinary frequency; hematuria; renal colic; nephrotic syndrome.
HEMA: Anemia; hemolytic anemia (possibly related to G-6-PD deficiency); aplastic anemia.
HEPA: Hepatic necrosis.
OTHER: Hypersensitivity reactions; anaphylaxis; fever; flushing; exacerbation of gout; uric acid stones; costovertebral pain.
Interacts with many other drugs by altering their clearance and elimination.
Barbiturate anesthetics, dyphylline, methotrexate, oral hypoglycemic agents, zidovudine
Increased serum levels and effects of these drugs.
Inhibition of uricosuric effect of either drug.
Therapeutic Classification: antigout agents, uricosurics
Absorption: Well absorbed following oral administration.
Distribution: Crosses the placenta.
Protein Binding: 75–95%.
Metabolism/Excretion: Mostly metabolized by the liver; 10% excreted unchanged in the urine.
Half-life: 4–17 hr.
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal